Deutsche Bank boosted their price objective on shares of DaVita HealthCare Partners (NYSE:DVA) from $68.00 to $72.00 in a research note issued on Monday, Stock Ratings Network reports. The firm currently has a “buy” rating on the stock. Deutsche Bank’s price target indicates a potential upside of 27.34% from the stock’s previous close.
Shares of DaVita HealthCare Partners (NYSE:DVA) traded up 8.22% during mid-day trading on Monday, hitting $61.19. The stock had a trading volume of 5,375,555 shares. DaVita HealthCare Partners has a one year low of $52.23 and a one year high of $65.665. The stock’s 50-day moving average is $57.19 and its 200-day moving average is $58.86. The company has a market cap of $13.015 billion and a P/E ratio of 20.89.
DaVita HealthCare Partners (NYSE:DVA) last announced its earnings results on Tuesday, November 5th. The company reported $0.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.96 by $0.02. The company had revenue of $3.00 billion for the quarter, compared to the consensus estimate of $2.93 billion. During the same quarter in the prior year, the company posted $1.56 earnings per share. The company’s quarterly revenue was up 54.2% on a year-over-year basis. Analysts expect that DaVita HealthCare Partners will post $3.80 EPS for the current fiscal year.
Other equities research analysts have also recently issued reports about the stock. Analysts at Piper Jaffray Cos. set a $73.00 price target on shares of DaVita HealthCare Partners in a research note to investors on Monday. Finally, analysts at Zacks reiterated a “neutral” rating on shares of DaVita HealthCare Partners in a research note to investors on Wednesday, November 6th. They now have a $59.00 price target on the stock. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and five have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $109.55.
DaVita HealthCare Partners Inc, formerly DaVita Inc, is a provider of dialysis services in the United States for patients suffering from chronic kidney failure, also known as end stage renal disease (NYSE:DVA).
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.